Validation of a small molecule inhibitor of PDE6D-RAS interaction with potent anti-leukemic effects

Sara Canovas Nunes, Serena De Vita, Andrew Anighoro, François Autelitano, Edward Beaumont, Pamela Klingbeil, Meaghan McGuinness, Beatrice Duvert, Chad E. Harris, Lu Yang, Sheela Pangeni Pokharel, Chun‐Wei Chen, Monika Ermann, David A. Williams, Haiming XubioRxiv 2022 · DOI

TL;DR

This paper identifies a novel therapeutic strategy for high-risk leukemias by targeting PDE6D, a chaperone protein essential for RAS signaling. The small molecule DW0254 effectively inhibits PDE6D, leading to RAS mislocalization, RAC inhibition, and potent anti-leukemic effects with low toxicity to healthy cells.

What Problem Does This Paper Address?

RAS mutations are a significant driver of relapse and chemotherapy resistance in high-risk leukemias, particularly acute lymphoblastic leukemia (ALL). However, directly targeting RAS proteins has proven challenging and largely unsuccessful. Previous research has shown that RAS-mediated transformation and leukemia cell survival are dependent on the activity of a related GTPase, RAC. This led the authors to hypothesize that targeting RAC could be a viable therapeutic approach for RAS-mutated tumors. The paper aims to identify and validate small molecules that can inhibit RAC activation and demonstrate anti-leukemic efficacy.

Methods

The study employed a multi-pronged approach:

  • Virtual and Biological Screening: An Evotec library of compounds was screened virtually for drug-like properties and shape-based pharmacophores of known RAC inhibitors. Promising candidates were then subjected to a biological screen to assess their inhibition of leukemic cell growth and toxicity to normal bone marrow progenitors.
  • Chemical Proteomics (Photoaffinity Labeling - PAL): To identify the direct molecular target of the lead compound DW0254, a photoaffinity labeling probe was synthesized. This probe, when activated by UV light, covalently binds to its target protein. Subsequent mass spectrometry (PAL-MS) was used to identify proteins that were labeled by the probe, especially in the presence of DW0254.
  • Biophysical Methods (Isothermal Titration Calorimetry - ITC): ITC was used to measure the binding affinity and thermodynamic parameters of DW0254 and other compounds to the identified target protein.
  • Structural Biology (Crystallography): Crystal structures of PDE6D in complex with DW0254 and another inhibitor (Deltarasin) were determined to understand their binding modes and interactions within the hydrophobic pocket.
  • Genetic Screens (Saturation Mutagenesis): A CRISPR-based saturation mutagenesis screen was performed on PDE6D to identify specific residues critical for DW0254 binding and to generate resistant cell lines.
  • Cellular Assays: Various assays were used to assess cell viability, apoptosis, cell cycle progression, RAC activation (GTP-RAC pull-down), RAS localization (fluorescent imaging), and downstream signaling pathways (Western blotting for phospho-AKT and phospho-ERK).
  • In Vivo Xenograft Model: The anti-leukemic efficacy of DW0254 was evaluated in a murine xenograft model using luciferase-expressing leukemia cells.

Datasets

  • Evotec compound library: Used for virtual and biological screening.
  • Published RAC inhibitors: Used to define shape-based pharmacophores for virtual screening.
  • Leukemia cell lines: A panel of ALL and AML cell lines with diverse RAS mutation statuses were used for in vitro testing.
  • Normal bone marrow progenitors: Used to assess the toxicity of candidate compounds.
  • Recombinant human PDE6D and RAC1 proteins: Used for biophysical and biochemical assays.
  • PDB database: Used for structural modeling and comparison.
  • CRISPR-Cas9 sgRNA library: Designed to target human PDE6D for mutagenesis screens.

Key Insights and Ideas

  • PDE6D as a novel therapeutic target: The study strongly implicates PDE6D, a RAS chaperone, as a critical mediator of RAS signaling in leukemia and a viable target for anti-leukemic therapy.
  • DW0254's mechanism of action: DW0254 inhibits PDE6D, leading to the mislocalization of RAS from the plasma membrane to the cytoplasm. This disruption prevents downstream signaling through PI3K/AKT and MAPK/ERK pathways, ultimately inhibiting RAC activation and leukemic cell survival.
  • Distinct binding modes: DW0254 and Deltarasin, another PDE6D inhibitor, bind to PDE6D's hydrophobic pocket but interact with different residues, suggesting they may target distinct conformations of the protein. This difference is highlighted by the resistance of R48delV49del PDE6D mutants to DW0254 but not Deltarasin.
  • Synergistic effects of combination therapy: Despite targeting the same protein, DW0254 and Deltarasin showed synergistic anti-leukemic effects in vitro, suggesting potential for combination therapies that exploit different PDE6D conformations.
  • Low toxicity profile: DW0254 demonstrated low toxicity to healthy CD34+ hematopoietic progenitor cells, indicating a favorable therapeutic window.

Key Results

  • Identification of DW0254: DW0254 was identified as a potent inhibitor of RAC activation with significant anti-leukemic activity in a panel of ALL and AML cell lines, with IC50 values in the low micromolar range.
  • PDE6D as the direct target: Photoaffinity labeling and mass spectrometry identified PDE6D as the direct molecular target of DW0254.
  • Mutations conferring resistance: Saturation mutagenesis identified mutations in residues R48 and V49 within PDE6D's hydrophobic pocket as conferring resistance to DW0254.
  • Inhibition of RAS localization: DW0254 treatment caused the mislocalization of RAS from the plasma membrane to the cytosol.
  • Downstream pathway inhibition: DW0254 treatment led to decreased activation of PI3K/AKT and MAPK/ERK pathways, and inhibited RAC activation.
  • In vivo efficacy: In a murine xenograft model, DW0254 treatment of leukemia cells prior to transplantation significantly reduced tumor burden, demonstrating in vivo anti-leukemic activity.
  • Low toxicity: DW0254 showed minimal toxicity to healthy CD34+ cells.

Limitations and Future Work

  • In vivo PK limitations: Initial in vivo pharmacokinetic assays showed low solubility and rapid plasma clearance of DW0254, which limited direct in vivo treatment in the xenograft model. The study used an ex vivo treatment approach for the xenograft model. Future work could focus on optimizing the pharmacokinetic properties of DW0254 or its derivatives.
  • Additional targets: While PDE6D was identified as the primary target, another target with lower signal intensity was detected in one cell line, which is currently under validation.
  • Translational potential: The authors suggest that DW0254's low toxicity profile makes it a promising candidate for translational improvement. Further studies are warranted to explore its clinical potential, possibly in combination with other agents.
  • Role in differentiation: The paper notes that a role for PDE6D in blood cell differentiation has not been previously described, but low doses of Deltarasin affected colony counts. This suggests potential areas for further investigation.

Summary updated

Abstract

Abstract RAS mutations prevalent in high-risk leukemia have been linked to relapse and chemotherapy resistance. Efforts to directly target RAS proteins have been largely unsuccessful. However, since RAS-mediated transformation is dependent on signaling through the RAS-related C3 botulinum toxin substrate (RAC) small GTPase, we hypothesized that targeting RAC may be an effective therapeutic approach in RAS mutated tumors. Here we describe multiple small molecules capable of inhibiting RAC activation in acute lymphoblastic leukemia cell lines. One of these, DW0254, also demonstrates promising anti-leukemic activity in RAS-mutated cells. Using chemical proteomics and biophysical methods, we identified the hydrophobic pocket of phosphodiester 6 subunit delta (PDE6D), a known RAS chaperone, as a target for this compound. Inhibition of RAS localization to the plasma membrane upon DW0254 treatment is associated with RAC inhibition through a phosphatidylinositol-3-kinase/AKT-dependent mechanism. Our findings provide new insights on the importance of PDE6D-mediated transport for RAS-dependent RAC activation and leukemic cell survival.
BibTeX
@misc{nunes2022validation,
  author = {Sara Canovas Nunes and Serena De Vita and Andrew Anighoro and François Autelitano and Edward Beaumont and Pamela Klingbeil and Meaghan McGuinness and Beatrice Duvert and Chad E. Harris and Lu Yang and Sheela Pangeni Pokharel and Chun‐Wei Chen and Monika Ermann and David A. Williams and Haiming Xu},
  title = {{Validation of a small molecule inhibitor of PDE6D-RAS interaction with potent anti-leukemic effects}},
  year = {2022},
  doi = {10.1101/2022.03.14.484294},
  howpublished = {bioRxiv},
}
Figure